Dihydropyrimidine Dehydrogenase Deficiency Latest Advances

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: April 18, 2026

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Journal: JCO oncology practice

Published: March 26, 2026

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Journal: Clinical chemistry and laboratory medicine

Published: January 27, 2026

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Journal: Pharmacogenomics

Published: January 16, 2026

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Journal: Expert opinion on drug metabolism & toxicology

Published: January 08, 2026

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Journal: JCO global oncology

Published: November 19, 2025

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study.

Journal: Frontiers in pharmacology

Published: October 25, 2025

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Journal: British journal of clinical pharmacology

Published: October 21, 2025

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity.

Journal: Genetics

Published: September 15, 2025

Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.

Journal: BMJ case reports

Published: August 31, 2025

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.

Journal: JCO precision oncology

Published: July 10, 2025

Dihydropyrimidine Dehydrogenase Deficiency Latest Advances

Find the Latest Research About Dihydropyrimidine Dehydrogenase Deficiency

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Toxicity of Capecitabine and Oxaliplatin as Adjuvant Therapy for Stage III Colorectal Cancer Patients With Diverting Stoma.

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Capillary dried blood microsampling is not suited for dihydropyrimidine dehydrogenase (DPD) phenotyping.

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Dihydropyrimidine dehydrogenase testing: capturing what standard genotyping misses with next-generation sequencing.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Bringing 5-FU monitoring home: microsampling as the potential next step beyond DPD deficiency screening.

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study.

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study.

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Clinical response to capecitabine in a DPYD*2A homozygous patient: Case report and therapeutic guidance.

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity.

Functional studies of human variants in C. elegans link iron metabolism to DPD deficiency and 5-FU sensitivity.

Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.

Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing.